1. Home
  2. EVR vs EXAS Comparison

EVR vs EXAS Comparison

Compare EVR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVR
  • EXAS
  • Stock Information
  • Founded
  • EVR 1995
  • EXAS 1995
  • Country
  • EVR United States
  • EXAS United States
  • Employees
  • EVR N/A
  • EXAS N/A
  • Industry
  • EVR Investment Managers
  • EXAS Medical Specialities
  • Sector
  • EVR Finance
  • EXAS Health Care
  • Exchange
  • EVR Nasdaq
  • EXAS Nasdaq
  • Market Cap
  • EVR 11.7B
  • EXAS 11.0B
  • IPO Year
  • EVR 2006
  • EXAS N/A
  • Fundamental
  • Price
  • EVR $308.02
  • EXAS $67.15
  • Analyst Decision
  • EVR Buy
  • EXAS Strong Buy
  • Analyst Count
  • EVR 9
  • EXAS 18
  • Target Price
  • EVR $320.11
  • EXAS $72.44
  • AVG Volume (30 Days)
  • EVR 421.0K
  • EXAS 2.9M
  • Earning Date
  • EVR 10-29-2025
  • EXAS 11-03-2025
  • Dividend Yield
  • EVR 1.09%
  • EXAS N/A
  • EPS Growth
  • EVR 61.11
  • EXAS N/A
  • EPS
  • EVR 12.55
  • EXAS N/A
  • Revenue
  • EVR $3,542,875,000.00
  • EXAS $3,082,033,000.00
  • Revenue This Year
  • EVR $24.72
  • EXAS $16.68
  • Revenue Next Year
  • EVR $17.06
  • EXAS $12.36
  • P/E Ratio
  • EVR $24.52
  • EXAS N/A
  • Revenue Growth
  • EVR 27.03
  • EXAS 14.47
  • 52 Week Low
  • EVR $148.63
  • EXAS $38.81
  • 52 Week High
  • EVR $364.42
  • EXAS $72.81
  • Technical
  • Relative Strength Index (RSI)
  • EVR 47.21
  • EXAS 62.39
  • Support Level
  • EVR $307.51
  • EXAS $66.14
  • Resistance Level
  • EVR $324.28
  • EXAS $69.08
  • Average True Range (ATR)
  • EVR 12.09
  • EXAS 2.28
  • MACD
  • EVR 1.36
  • EXAS -0.26
  • Stochastic Oscillator
  • EVR 45.72
  • EXAS 45.06

About EVR Evercore Inc.

Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: